Our results and the published reports indicate low morbidity and long survival of patients with indolent small intestinal CD4+ T-cell lymphomas, often exceeding a decade [14], [16], [17] in contrast to the median overall survival of 10 and 7 months, respectively, for patients with EATL types I and II. The gene discussed is CD4; the disease is T-cell non-Hodgkin lymphoma.